Sponsored Links

Athletic boost from growth hormone may be mental

Tue Jun 17, 2008 3:15pm EDT
 
[-] Text [+]

NEW YORK (Reuters Health) - The "placebo effect" may play a part in the athletic performance-enhancing effects of growth hormone, particularly in men, new findings suggest.

"Athletes are doping with growth hormone to improve performance, despite any firm scientific evidence that it does so," Dr. Kenneth K. Ho said at the Endocrine Society's annual meeting in San Francisco.

Ho, of the Garvan Institute of Medical Research, Sydney, Australia and colleagues randomly assigned 64 young adult recreational athletes to get growth hormone or an inactive placebo, without the participants or researchers knowing which was which, for 8 weeks.

"We found that athletes who believed that they were taking growth hormone actually felt that their performance had improved and actually demonstrated improvement in physical performance, even though they were taking a placebo," Ho reported.

In general, everyone showed a small improvement in performance after the study, usually about 1 to 2 percent, he said.

"This is a well recognized training effect. But among those who wrongly thought they received growth hormone, the performance enhancement was about twice that -- between 3 percent and 5 percent," Ho noted. "This phenomenon was far greater in men than in women."

"It is clear from our study that the mind plays amazing tricks on the body and this placebo effect has been known for many centuries. To our knowledge, this is the first study of the examination of a placebo effect in a sporting arena," Ho added.

The study was funded by the World Anti-Doping Agency and the Australian Government Anti-Doping Research Program.

 

Editor's Choice

A selection of our best photos from the past 24 hours.  Slideshow 

Most Popular on Reuters

  • Articles
  • Video
A customer shops for medicine at a Portland, Oregon drugstore July 31, 2005. REUTERS/Richard Clement RC/YH
Blame game slows growth of personalized medicine

Expectation has been building for a decade that an era of personalized medicine will transform the global drugs business, but the reality is a slow start and an angry blame game between scientists, marketers and regulators.  Full Article